Enliven (ELVN) Insider Sale of $345,000 Amid 130% Stock Surge
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowLori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), sold 10,000 shares for approximately $345,000 on June 5, 2026, at a weighted average price of $34.54. This transaction marked Kunkel's first open-market sale, representing 16% of her direct holdings, reducing her shares from 61,884 to 51,884. At the time, ELVN shares returned 62.4% over the past year, closing at $34.71 on the transaction date before appreciating to $50 by the following Friday. The sale was executed under a Rule 10b5-1 trading plan set on March 6, 2026, amid strong market performance for the firm’s oncology therapeutics.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
